Silence Inks Delivery Tech Evaluation Deal with Mireven

Aug 23, 2012

Premium

Silence Therapeutics this week announced that it has struck a deal under which its delivery technologies will be evaluated by Australian microRNA drug developer Mireven for use with its therapeutic candidates.

Silence will formulate a mimic of miR-7 using its three lipid-based delivery technologies: AtuPlex, which is used in the company's phase I siRNA cancer drug Atu-027; DACC, which selectively targets the lung endothelium; and DBTC, which targets liver cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Ultrasensitive Digital Immunoassay for PSA by Single Molecule Array Simoa Technology in Prostatectomy Patients

RNAGEM - mRNA Profiles as Close to Biological Reality as Possible

Oct

23

Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.

Menu